To the Editor: Dr Adler recently commented on the Institute of Medicine recommendations to help foster progress in women's health by increasing the availability of sex-specific data.1 We believe that the best way to guarantee that adequate sex-specific data are acquired and examined is if insurers require such data for coverage of drugs, devices, or other medical interventions. The Centers for Medicare & Medicaid Services (CMS) should lead the way, both because its funding comes from taxpayers and because many insurers follow their coverage decisions.
Dhruva SS, Redberg RF. Clinical Trial Enrollment and Progress in Women’s Health. JAMA. 2011;305(12):1197–1198. doi:10.1001/jama.2011.347
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: